The series is stated in the current share scale after splits; dividends are not included in the price
Bristol Myers Squibb is passing through patent expiry on several large medicines at once and is closing the gap by acquisition.
The company is strong in oncology and immunology: anticoagulants, immuno-oncology, multiple myeloma treatments. The problem is known in advance and priced in: key products lose protection over the next few years, and their revenue will collapse under generic pressure.
The replacement strategy is dealmaking: acquiring companies with late-stage assets in neuroscience, oncology and cardiology. That route is faster than in-house development but more expensive and adds debt, and the outcome depends on whether the acquired medicines meet expectations.
A separate factor is price negotiation with US government programmes: the drugs costing the budget most are selected first, which directly reduces revenue on the most successful products. The company pays a dividend high by sector standards.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Bristol-Myers Squibb Company (BMY) is a company in the Health care sector; its shares trade on NYSE.
The price of Bristol-Myers Squibb Company (BMY) on November 2, 2026 is 62.66 $, +0.28 % on the day. Over 52 weeks the stock traded between 42.52 $ and 68.64 $; the price now sits 77 % of the way up that range. Over the past year the price changed by +38.89 %. The P/E ratio is 13.65, which is below the sector median (24.61). Market capitalization is 126.70 billion $, rank 8 among 380 stocks of the same industry with a known capitalization.
Bristol-Myers Squibb Company trades on NYSE under the ticker BMY. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BMY has traded between 42.52 $ and 68.64 $. As of 2 November 2026 the price stood 69.10 % of the way from the 52-week low to the high.
Over one year BMY shares rose 38.89 %; over six months they rose 2.73 %. Volatility over 90 days is 27.77 %. Dividends are not included: this is price change only, as of 2 November 2026.
BMY trades at a price-to-earnings ratio of 13.6, below the sector median of 24.6. Price to sales is 2.6, below the sector median of 3.6. Price to book is 5.7, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Bristol-Myers Squibb Company reported revenue of 49.2B $ and net income of 9.3B $ over the last four quarters. Net margin is 18.87 %. Revenue changed by +3.11 % year over year. Earnings per share are 4.54 $. Market capitalisation is 126.7B $.
BMY has a return on equity of 41.59 %, above the sector median of −40.58 %. Return on assets is 10.59 %, above the sector median of −30.08 %.
